Saturday, July 11, 2026

Drug profile · INN

phenacemide

phenacemide (PHENURONE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — phenacemide
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

phenacemide (PHENURONE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN phenacemide
Brand PHENURONE
Mechanism Sodium channel alpha subunit blocker
Target Sodium channel alpha subunit
Route ORAL
Formulation TABLET

Mechanism of action

Sodium channel alpha subunit blocker

Primary target: Sodium channel alpha subunit

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. carbamazepine Sodium channel alpha subunit blocker
  2. disopyramide phosphate Sodium channel alpha subunit blocker
  3. eslicarbazepine acetate Nervous system (N03)
  4. fosphenytoin sodium Sodium channel alpha subunit blocker
  5. lacosamide Nervous system (N03)
  6. lamotrigine Sodium channel alpha subunit blocker

Frequently asked questions

What is phenacemide?

phenacemide (PHENURONE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for phenacemide?

PHENURONE is a marketed brand name for phenacemide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of phenacemide?

phenacemide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.